An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'. The study aims to identify changes in the production and metabolism of catecholamines by measuring the substance which starts the chain of catecholamine metabolism called tyrosine in patients before, during and after 5 days of taking Belzutifan 120mg daily.

NCT Number	NCT07680205
Lead Sponsor	Cambridge University Hospitals NHS Foundation Trust Collaborators: University of Cambridge
Conditions	Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma, Pheochromocytoma
Enrollment	12 participants
Start Date	2026-04-27
Primary Completion	2027-04 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-02